Zobrazeno 1 - 10 of 14 pro vyhledávání: '"J V Cox"'
1
SK&F107647: A Synthetic Hematoregulatory Peptide in Patients With Solid Tumor Malignancies
Autor: J, Nemunaitis, D E, Martin, D L, Willis, M I, Freed, B, Levitt, D A, Richards, J V, Cox, G T, Kimmel, W J, Hyman, D K, Jorkasky, D R, Brocks
Publikováno v: American Journal of Clinical Oncology. 21:189-194
SKF107647 is a synthetic hematoregulatory peptide (HP) increases both the number and function of progenitor cells, enabling improved survival after lethal myelosuppression, lethal fungal infection, and lethal herpes simplex virus infection in murine
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fb35273021504e0b08512ed426f8f30
https://doi.org/10.1097/00000421-199804000-00020
Zobrazit plný text záznamu
2
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
Autor: L B, Saltz, J V, Cox, C, Blanke, L S, Rosen, L, Fehrenbacher, M J, Moore, J A, Maroun, S P, Ackland, P K, Locker, N, Pirotta, G L, Elfring, L L, Miller
Publikováno v: The New England journal of medicine. 343(13)
The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4df76fc1bacc44e9efd5d30b2facb1a8
https://pubmed.ncbi.nlm.nih.gov/11450667
Zobrazit plný text záznamu
3
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
Autor: M L, Rothenberg, J V, Cox, R F, DeVore, J D, Hainsworth, R, Pazdur, S E, Rivkin, J S, Macdonald, C E, Geyer, J, Sandbach, D L, Wolf, J S, Mohrland, G L, Elfring, L L, Miller, D D, Von Hoff
Publikováno v: Cancer. 85(4)
This multicenter, Phase II trial was performed to evaluate the antitumor activity and toxicity of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma that had recurred or progressed after 5-fluorouracil (5-FU)-based chemotherapy.CPT-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::69291afbc34eecc005de678b8b1a38d2
https://pubmed.ncbi.nlm.nih.gov/10091755
Zobrazit plný text záznamu
4
A Dilatational-Interface Model for Bond
Autor: J V Cox
Publikováno v: SP-180: Bond and Development of Reinforcement - A Tribute to Dr. Peter Gergely.
A bond model is presented that uses an interface idealization of the bond phenomena and incorporates dilation to characterize the wedging effect of splitting failures, it may provide an approach for characterizing the observed experimental response o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d4ce6ce28d9ad51a8c63e50b7e7fd839
https://doi.org/10.14359/5873
Zobrazit plný text záznamu
6
Four variant chicken erythroid AE1 anion exchangers. Role of the alternative N-terminal sequences in intracellular targeting in transfected human erythroleukemia cells
Autor: K H, Cox, T L, Adair-Kirk, J V, Cox
Publikováno v: The Journal of biological chemistry. 270(34)
Four variant AE1 anion exchangers with predicted molecular masses of approximately 99, approximately 102, approximately 104, and approximately 108 kDa are expressed in chicken erythroid cells. These variant polypeptides differ in sequence only at the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d7b67c8d506852aca282c49e6484ec34
https://pubmed.ncbi.nlm.nih.gov/7649985
Zobrazit plný text záznamu
7
Effective management of patients receiving XELOX: Evaluation of impact of dose modifications on outcome in patients from the NO16966, NO16967, and NO16968 trials
Autor: H.-J. Schmoll, N. Scotto, J. Cassidy, J. V. Cox
Publikováno v: Journal of Clinical Oncology. 29:497-497
497 Background: In patients (pts) with metastatic colorectal cancer (MCRC), XELOX is non-inferior to FOLFOX4 in terms of PFS and OS as either first-line (NO16966, Cassidy et al. JCO 2008) or second-line therapy (NO16967, Rothenberg et al. Ann Oncol 2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab9ec3e740aae81bb47d7c426b974c29
https://doi.org/10.1200/jco.2011.29.4_suppl.497
Zobrazit plný text záznamu
8
An eosinophilic fibrohistiocytic lesion of bone marrow in a patient with Hodgkin's disease. A potential for morphologic confusion
Autor: J V, Cox, E P, Balaban, S E, Demian, R G, Sheehan
Publikováno v: Cancer. 68(8)
The eosinophilic fibrohistiocytic lesion of bone marrow (EFLBM) is characterized by collections of elongated "fibrohistiocytic" cells in association with lymphocytes, eosinophils, and plasma cells. The fibrohistiocytic cells are mast cells, and many
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f4b0bff75d72543616fbfc8663a2c79d
https://pubmed.ncbi.nlm.nih.gov/1913527
Zobrazit plný text záznamu
9
A Phase II study of gemcitabine plus zoledronic acid in subjects with Stage IV pancreatic cancer
Autor: Michael A. Monticelli, J. V. Cox, Kristi A. Boehm, Marcus A. Neubauer, John Sandbach, Thomas H. Cartwright, Des Ilegbodu, Lina Asmar, D. McCollum
Publikováno v: Journal of Clinical Oncology. 24:14002-14002
14002 Background: Gemcitabine, the standard chemotherapy for advanced pancreatic cancer (APC), produces low response rates and short time to progression. Preclinical studies suggest that zoledronic acid inhibits pancreatic cell lines by interfering w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f841753d8c25595ceddc19d4b5dfa21
https://doi.org/10.1200/jco.2006.24.18_suppl.14002
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje